6% HYDROXYETHYL STARCH 130/0.4 IN 0.9% SODIUM CHLORIDE INJECTION
|
|
- Kelley Sabrina Joseph
- 6 years ago
- Views:
Transcription
1 VetStarch 6% HYDROXYETHYL STARCH 130/0.4 IN 0.9% SODIUM CHLORIDE INJECTION CAUTION: Federal Law (USA) restricts this drug to use by or on the order of a licensed veterinarian. HIGHLIGHTS OF PRESCRIBING INFORMATION: These highlights do not include all of the information needed to use VetStarch safely and effectively. See full prescribing information for VetStarch. VetStarch TM (6% HYDROXYETHYL STARCH 130/0.4 IN 0.9% SODIUM CHLORIDE INJECTION) For administration by intravenous infusion. INDICATIONS AND USAGE: VetStarch is a plasma volume substitute indicated for the treatment and prophylaxis of hypovolemia. DOSAGE AND ADMINISTRATION: Administer by intravenous infusion only. Daily dose and rate of infusion depend on the patient s blood loss, hemodynamics and on the hemodilution effects Initiate infusion slowly due to possible anaphylactoid reactions DOSAGE FORMS AND STRENGTHS: 250 ml and 500 ml flexible plastic intravenous solution containers. Each 100 ml contains 6 g hydroxyethyl starch 130/0.4 in isotonic sodium chloride injection. CONTRAINDICATIONS: Known hypersensitivity to hydroxyethyl starch Fluid overload e.g., pulmonary edema and congestive heart failure Renal failure with oliguria or anuria not related to hypovolemia Patients receiving dialysis Severe hypernatremia or severe hyperchloremia Intracranial bleeding WARNINGS AND PRECAUTIONS: Anaphylactoid and hypersensitivity reactions Avoid fluid overload; adjust dosage in patients with cardiac or renal dysfunction In severe dehydration, a crystalloid solution should be given first Observe caution in patients with severe liver disease or bleeding disorders Monitor kidney function, fluid balance and serum electrolytes In humans elevated serum amylase values may occur and interfere with the diagnosis of pancreatitis High dosages may cause dilution of blood components ADVERSE REACTIONS: Anaphylactoid/hypersensitivity reactions can occur. Most common adverse reactions are pruritus, hemodilution (resulting in dilution of blood components, e.g., coagulation factors and other plasma proteins, and in a decrease in hematocrit). To report SUSPECTED ADVERSE REACTIONS, call Zoetis Inc. at DRUG INTERACTIONS: No interactions with other drugs or nutritional products are known. The safety and compatibility of additives have not been established. USE IN SPECIFIC POPULATIONS: Renal impaired: Use care in dosage selection. After reviewing the Highlights Section, please read the following full prescribing information for this drug. Revised: July C
2 FULL PRESCRIBING INFORMATION: CONTENTS 1. INDICATIONS AND USAGE 2. DOSAGE AND ADMINISTRATION 2.1 Adult Dose 2.2 Directions for Use of VetStarch TM 3. DOSAGE FORMS AND STRENGTHS 4. CONTRAINDICATIONS 5. WARNINGS AND PRECAUTIONS 5.1 General Warnings and Precautions 5.2 Monitoring: Laboratory Tests 5.3 Interference with Laboratory Tests 6. ADVERSE REACTIONS 6.1 Overall Adverse Reaction Profile 7. DRUG INTERACTIONS 8. USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.2 Labor and Delivery 8.3 Renal Impairment 9. OVERDOSAGE 10. DESCRIPTION 11. CLINICAL PHARMACOLOGY 11.1 Mechanism of Action 12. NONCLINICAL TOXICOLOGY 12.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 12.2 Animal Toxicology and Pharmacology Toxicology Pharmacology 13. REFERENCES 14. HOW SUPPLIED/STORAGE AND HANDLING
3 FULL PRESCRIBING INFORMATION For Animal Use Only CAUTION: Federal Law (USA) restricts this drug to use by or on the order of a licensed veterinarian. 1. INDICATIONS AND USAGE VetStarch TM (6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection) is indicated for the treatment and prophylaxis of hypovolemia. It is not a substitute for red blood cells or coagulation factors in plasma. 2. DOSAGE AND ADMINISTRATION VetStarch is administered by intravenous infusion only. The daily dose and rate of infusion depend on the patient s blood loss, on the maintenance or restoration of hemodynamics and on the hemodilution (dilution effect). VetStarch can be administered repetitively over several days. [see Warnings and Precautions (5)] The initial 10 to 20 ml should be infused slowly, keeping the patient under close observation due to possible anaphylactoid reactions. [see General Warnings and Precautions (5.1)] 2.1 Adult Dose As a general recommendation, the class of synthetic colloids are prescribed at doses up to 20 ml per kg of body weight per day in small animal patients. 1 In a 30 kg patient, this is a dose of 600 ml of VetStarch (equivalent to 1.2 g hydroxyethyl starch and 3.1 meq sodium per kg of body weight). The use of 6% hydroxyethyl starch 130/0.4 has been dosed at 50 ml per kg of body weight per day in human studies Directions for Use of VetStarch Check the solution composition, lot number and expiry date, inspect the container for damage or leakage, if damaged do not use. Use opening aid to remove overwrap. Identify the blue infusion (administration) port. Break off the blue tamper evident cover from the infusion port. Hang the bag on the infusion stand. Press drip chamber to get fluid level. Prime infusion set. Connect and adjust the flow rate. Close roller clamp. Insert the spike until the clear plastic collar of the port meets the shoulder of the spike. Use a non-vented standard infusion set. Close air inlet. 1. Do not remove the IV container from its overwrap until immediately before use. 2. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. 3. Do not administer unless the solution is clear, free from particles and the IV container is undamaged. 4. VetStarch should be used immediately after insertion of the administration set. 5. Do not vent. 6. If administered by pressure infusion, air should be withdrawn or expelled from the bag through the medication/ administration port prior to infusion. 7. Discontinue the infusion if an adverse reaction occurs. 8. It is recommended that administration sets be changed at least once every 24 hours. 9. For single use only. Discard unused portion. INCOMPATIBILITIES The safety and compatibility of additives have not been established. 3. DOSAGE FORMS AND STRENGTHS 250 ml and 500 ml flexible plastic intravenous solution containers are available. Each 100 ml contains 6 g hydroxyethyl starch 130/0.4 in isotonic sodium chloride injection.
4 4. CONTRAINDICATIONS The use of VetStarch TM is contraindicated in the following conditions: Known hypersensitivity to hydroxyethyl starch [see General Warnings and Precautions (5.1)] Fluid overload (hyperhydration) and especially in cases of pulmonary edema and congestive heart failure Renal failure with oliguria or anuria not related to hypovolemia Patients receiving dialysis treatment Severe hypernatremia or severe hyperchloremia Intracranial bleeding 5. WARNINGS AND PRECAUTIONS 5.1 General Warnings and Precautions Anaphylactoid reactions (bradycardia, tachycardia, bronchospasm, non-cardiac pulmonary edema) have been reported with solutions containing hydroxyethyl starch. 3 If a hypersensitivity reaction occurs, administration of the drug should be discontinued immediately and the appropriate treatment and supportive measures should be undertaken until symptoms have resolved. [see Adverse Reactions (6)] Fluid status and rate of infusion should be assessed regularly during treatment, especially in patients with cardiac insufficiency or severe kidney dysfunction. In cases of severe dehydration, a crystalloid solution should be given first. Generally, sufficient fluid should be administered in order to avoid dehydration. Caution should be observed before administering VetStarch to patients with severe liver disease or severe bleeding disorders. With the administration of certain hydroxyethyl starch solutions, disturbances of blood coagulation can occur depending on the dosage. 4,5 5.2 Monitoring: Laboratory Tests Clinical evaluation and periodic laboratory determinations are necessary to monitor fluid balance, electrolyte concentrations, kidney function, acid-base balance, and coagulation parameters during prolonged parenteral therapy, or whenever the patient s condition warrants such evaluation. 5.3 Interference with Laboratory Tests In humans, elevated serum amylase levels may be observed temporarily following administration of the product and can interfere with the diagnosis of pancreatitis. At high dosages the dilutional effects may result in decreased levels of coagulation factors and other plasma proteins and a decrease in hematocrit. 4,5 6. ADVERSE REACTIONS 6.1 Overall Adverse Reaction Profile Products containing hydroxyethyl starch may lead to anaphylactoid reactions (hypersensitivity, mild influenza-like symptoms, bradycardia, tachycardia, bronchospasm, non-cardiac pulmonary edema). In the event of an intolerance reaction, the infusion should be discontinued immediately and the appropriate emergency medical treatment initiated. [see General Warnings and Precautions (5.1)] Skin and subcutaneous tissue disorders in humans; prolonged administration of high dosages of hydroxyethyl starch may cause pruritus (itching) which is an undesirable effect observed with all hydroxyethyl starches. Investigations; at high doses, the dilutional effects may result in decreased levels of coagulation factors and other plasma proteins, and a decrease in hematocrit. [see Interference with Laboratory Tests (5.3)] 7. DRUG INTERACTIONS No interactions with other drugs or nutritional products are known. The safety and compatibility of other additives have not been established. 4,5 [see Directions for Use of VetStarch (2.2)] 8. USE IN SPECIFIC POPULATIONS 8.1 Pregnancy The type of hydroxyethyl starch present in VetStarch had no teratogenic properties in rats or rabbits. At 5 g/kg of body weight per day, administered as a bolus injection, fetal retardations and embryolethal effects were observed in rats and rabbits, respectively. In rats, a bolus injection of this dose during pregnancy and lactation reduced body weight of offspring and induced developmental delays. All adverse effects were seen exclusively at maternal toxic doses due to fluid overload. [see Toxicology (12.2.1)] Fertility studies on directly exposed animals have not been conducted. 8.2 Labor and Delivery Information on the use of VetStarch during labor or delivery is unknown. 8.3 Renal Impairment VetStarch is mainly excreted by the kidneys, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Volume status, infusion rate, and urine output should be closely monitored.
5 9. OVERDOSAGE As with all plasma volume substitutes, overdosage can lead to overloading of the circulatory system (e.g., pulmonary edema). In this case, the infusion should be stopped immediately and, if necessary, a diuretic should be administered. [see General Warnings and Precautions (5.1)] 10. DESCRIPTION VetStarch TM (6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection) is a clear to slightly opalescent, colorless to slightly yellow, sterile, non-pyrogenic, isotonic solution for intravenous administration using sterile equipment. Each 100 ml of the solution contains: Hydroxyethyl Starch 130/0.4 6 g Sodium Chloride USP in Water for Injection USP 900 mg ph adjusted with Sodium Hydroxide USP or Hydrochloric Acid USP Electrolytes (meq/l): Sodium 154, Chloride 154, ph 4 to 5.5. Calculated osmolarity 308 mosmol/l. The hydroxyethyl starch contained in VetStarch is a synthetic colloid for use in plasma volume replacement. The chemical name of hydroxyethyl starch is poly(o-2-hydroxyethyl) starch. The structural formula of hydroxyethyl starch is: R = -H, -CH 2 CH 2 OH R 1 = -H, -CH 2 CH 2 OH or glucose units VetStarch is packaged in 250 ml and 500 ml flexible plastic containers made from coextruded polyolefin and is free of PVC, plasticizers, adhesives or latex (Non-DEHP, Latex-free). The container offers an air-closed system and can be used with non-vented IV sets which prevent external air contamination. The container is collapsible and can be used in emergency cases for pressure infusion. 11. CLINICAL PHARMACOLOGY 11.1 Mechanism of Action VetStarch contains hydroxyethyl starch in a colloidal solution which expands plasma volume when administered intravenously. This effect depends on the mean molecular weight (130,000 daltons; range 110, ,000 daltons), the molar substitution by hydroxyethyl groups (0.4; range ) on glucose units of the starch, the pattern of hydroxyethyl substitution (C 2 /C 6 ratio) of approximately 9:1, and the concentration (6%), as well as the dosage and infusion rate. Hydroxyethyl starch is a derivative of thin boiling waxy corn starch, which mainly consists of a glucose polymer (amylopectin) predominately composed of α-1-4-connected glucose units with several α-1-6-branches. Substitution of hydroxyethyl groups on the glucose units of the polymer reduces the normal degradation of amylopectin by α-amylase in the body. The low molar substitution (0.4) is the main pharmacological determinant for the beneficial effects of VetStarch on pharmacokinetics, intravascular volume and hemodilution. 6 To describe the molecular weight and molar substitution characteristics of the hydroxyethyl starch in VetStarch, the compound is designated as hydroxyethyl starch 130/ NONCLINICAL TOXICOLOGY 12.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term studies in animals, to evaluate the carcinogenic potential of VetStarch, have not been performed. No mutagenic effects were observed with hydroxyethyl starch 130/0.4 10% solution in the following tests on mutagenic activity: Salmonella typhimurium reverse mutation assay (in vitro), mammalian cells in the in vitro gene mutation assay, assessment of the clastogenic activity in cultured human peripheral lymphocytes (in vitro), bone marrow cytogenetic test in Sprague-Dawley rats. Fertility studies on directly exposed animals have not been performed Animal Toxicology and Pharmacology Toxicology Three-month repeat infusion toxicology studies were conducted in rats and dogs in which three groups of animals were administered daily intravenous infusion over three hours. Dosing volumes of either 60 or 90 ml/kg body weight of hydroxyethyl starch 130/0.4 (10% solution), or 90 ml/kg 0.9% sodium chloride injection, were studied. Observed toxicity following repeat infusion of hydroxyethyl starch is consistent with the oncotic properties of the solution resulting in hypervolemia in the animals. There were no apparent gender-related effects on toxicity following repeat administration of hydroxyethyl starch 130/0.4 in rats or dogs. In reproduction studies in rats and rabbits, hydroxyethyl starch 130/0.4 (10% solution) had no teratogenic properties. Embryolethal effects were observed in rabbits at 5 g/kg body weight/day. In rats, bolus injection of this dose during pregnancy and lactation reduced body weight of offspring and induced developmental delays. Signs of fluid overload were seen in the dams. Hydroxyethyl starch 130/0.4 (10% solution) was observed to have no effect in studies assessing skin sensitization, antigenicity, and blood compatibility.
6 Pharmacology The pharmacodynamic effect of VetStarch TM was examined in a hemorrhagic shock model in conscious rats, and a hemodilution model in dogs. In both studies, the control group received pentastarch (6% hydroxyethyl starch 200/0.5). VetStarch was as effective as pentastarch in maintaining cardiopulmonary function during isovolemic hemodilution in beagle dogs. In the three-hour follow-up period, no additional administration of colloid was necessary. There were no differences in long-term survival of rats after a single administration of VetStarch and pentastarch solutions following induced hemorrhagic shock (67% and 50% blood loss). In the 67% induced bleeding group receiving VetStarch (N=6), the survival rate was 83% which is within the normal range for this type of experiment. In the corresponding pentastarch group, survival was 100%. Infusion of Ringer s lactate resulted in a 50% survival rate after a 50% blood loss and a 0% survival after a 67% blood loss. After multiple intravenous infusions of 0.7 g per kg body weight per day of 10% hydroxyethyl starch 130/0.4, or 10% hydroxyethyl starch 200/0.5 solution, during 18 consecutive days, the plasma hydroxyethyl starch concentration in rats treated with hydroxyethyl starch 130/0.4 was lower compared to rats treated with hydroxyethyl starch 200/0.5. Hydroxyethyl starch 130/0.4 was eliminated faster than hydroxyethyl starch 200/0.5. In both groups, clear signs of hydroxyethyl starch tissue storage were detected in lymph nodes and spleen. Numerous empty vacuoles in macrophages were observed. Only minimal cellular vacuolization was found in the liver and kidney. Histochemical differences between the groups were not observed. A study with 10% radiolabeled 14 C-hydroxyethyl starch 130/0.4 and 10% 14 C-hydroxyethyl starch 200/0.5 solutions was carried out. 7 In animals treated with hydroxyethyl starch 130/0.4, radioactivity decreased from 4.3% of the total administered dose (2.6 g hydroxyethyl starch 130/0.4 per animal) on day 3 to 0.65% on day 52. In animals treated with hydroxyethyl starch 200/0.5, the 14 C activity decreased from 7.7% of the total administered dose (2.7 g hydroxyethyl starch 200/0.5 per animal) on day 3 to 2.45% on day 52. These results confirm the faster elimination and lower persistence of hydroxyethyl starch 130/0.4 in tissue. 13. REFERENCES 1. Silverstein D, Hopper K. Small Animal Critical Care Medicine. (2009). 2. Neff T., Doelberg M., Jungheinrich C., Sauerland A., Spahn D., Stocker R., Repetitive Large-Dose Infusion of the Novel Hydroxyethyl Starch 130/0.4 in Patients with Severe Head Injury. Anesth Analg 96 (2003): DiBartola, S. Fluid, Electrolyte, & Acid-Base Disorders in Small Animal Practice. (2011). 4. Smiley, et al. The Use of Hetastarch as Adjunct Therapy in 36 dogs with Hypoalbuminemia: a Phase Two Clinical Trial. J Vet Intern Med, 8 (1994): Smart, et al. The Effect of Hetastarch (670/0.75) In Vivo on Platelet Closure Time in the Dog. J Vet Emerg Crit Care, 19(5) (2009): Jungheinrich, C., Neff, T. Pharmacokinetics of hydroxyethyl starch. Clin Pharmacokinetik 44 (7) (2005): Leuschner, J., Opitz, J., Winkler, A., Scharpf, R., Bepperling, F. Tissue storage of 14 C-labeled hydroxyethyl starch (HES) 130/0.4 and HES 200/0.5 after repeated intravenous administration to rats. Drugs R D, 4 (6) (2003): HOW SUPPLIED/STORAGE AND HANDLING VetStarch TM (6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection) for intravenous infusion is supplied in the following primary container and carton sizes: Polyolefin bag with overwrap: 250 ml and 500 ml Carton of 20 x 500 ml Carton of 30 x 250 ml Store at 15 to 25 C (59 to 77 F), Do not freeze For Customer Service call Distributed by: Zoetis Inc. Kalamazoo, MI Product of Norway
IMPORTANT DRUG WARNING
IMPORTANT DRUG WARNING Subject: New Warnings and Precautions, including Boxed Warning, for Voluven (6% Hydroxyethyl Starch 130/0.4 in 0.9% Sodium Chloride Injection) June 26, 2013 Dear Health Care Professional:
More informationVOLUVEN - hydroxyethyl starch 130/0.4 injection, solution Hospira Inc
VOLUVEN - hydroxyethyl starch 130/0.4 injection, solution Hospira Inc. ---------- HIGHLIGHT S OF PRESCRIBING INFORMAT ION These highlights do not include all the information needed to use Voluven prescribing
More information1.3.1 SPC, Labelling and Package Leaflet (Voluven Fresenius 6% Solution for Infusion)
1.3.1 SPC, Labelling and Package Leaflet (Voluven Fresenius 6% Solution for Infusion) 1.3.1 SUMMARY OF PRODUCT CHARACTERISTICS This medicinal product is subject to additional monitoring. This will allow
More informationPRESCRIBING INFORMATION. PENTASPAN* (10% Pentastarch in 0.9% Sodium Chloride Injection) Injection THERAPEUTIC CLASSIFICATION. Plasma Volume Expander
PRESCRIBING INFORMATION PENTASPAN* (10% Pentastarch in 0.9% Sodium Chloride Injection) Injection THERAPEUTIC CLASSIFICATION Plasma Volume Expander ACTION AND CLINICAL PHARMACOLOGY The colloidal properties
More informationSodium Chloride 0.9% Injection, FK Std.
Text for Prescribing Information: Sodium Chloride 0.9% Injection, FK Std. DESCRIPTION Sodium Chloride 0.9% Injection is a sterile nonpyrogenic intravenous solution that contains no bacteriostatic or antimicrobial
More informationVOLULYTE PRODUCT MONOGRAPH. 6% hydroxyethyl starch 130/0.4 in an isotonic electrolyte injection. Plasma Volume Expander
PRODUCT MONOGRAPH VOLULYTE 6% hydroxyethyl starch 130/0.4 in an isotonic electrolyte injection Plasma Volume Expander Fresenius Kabi Canada Ltd. 165 Galaxy Blvd, Suite 100 Toronto, ON M9W 0C8 Canada Date
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use 6% Hetastarch in 0.9% Sodium Chloride Injection safely and effectively. See full prescribing information
More informationSodium Chloride Injection, USP in VIAFLO Plastic Container
Sodium Chloride Injection, USP in VIAFLO Plastic Container DESCRIPTION Sodium Chloride Injection, USP is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment in single dose containers
More information*Sections or subsections omitted from the full prescribing information are not listed.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use GIAPREZA TM safely and effectively. See full prescribing information for GIAPREZA. GIAPREZA (angiotensin
More information3% Sorbitol Urologic Irrigating Solution in UROMATIC Plastic Container
3% Sorbitol Urologic Irrigating Solution in UROMATIC Plastic Container Description 3% Sorbitol Urologic Irrigating Solution is a sterile, nonpyrogenic, nonhemolytic, electrically nonconductive solution
More information45779C/Revised: April 2008 MANNITOL INJECTION, USP
45779C/Revised: April 2008 MANNITOL INJECTION, USP 25% For Intravenous Use and Urologic Irrigation DESCRIPTION: Mannitol is a 6-carbon sugar alcohol and has the following structure: C 6 H 14 O 6 182.17
More informationNORMOSOL -R MULTIPLE ELECTROLYTES INJECTION TYPE 1, USP For Replacing Acute Losses of Extracellular Fluid Flexible Plastic Container
NORMOSOL -R MULTIPLE ELECTROLYTES INJECTION TYPE 1, USP For Replacing Acute Losses of Extracellular Fluid Flexible Plastic Container R x only DESCRIPTION Normosol-R is a sterile, nonpyrogenic isotonic
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Aqupharm 3 Solution for Infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active ingredients Sodium Chloride Glucose Anhydrous
More informationCLINICAL PHARMACOLOGY
SODIUM CHLORIDE- sodium chloride injection, solution B. Braun Medical Inc. ---------- 0.9% Sodium Chloride Injection USP Partial Fill DESCRIPTION Each ml of 0.9% Sodium Chloride Injection USP contains:
More information3. PHARMACEUTICAL FORM Solution for infusion. A clear, slightly viscous liquid; it is almost colourless, yellow, amber or green.
1. NAME OF THE MEDICINAL PRODUCT Albutein 250 g/l, solution for infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Human albumin Albutein 250 g/l is a solution containing 250 g/l of total protein of
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Flexbumin 200 g/l is a solution containing 200 g/l (20%) of total protein of which at least 95% is human albumin.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Flexbumin 200g/l solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Flexbumin 200 g/l is a solution containing 200 g/l
More informationPRESCRIBING INFORMATION. Dextrose Injection USP. (Concentrated Dextrose for Intravenous Administration) 50% (500 mg/ml) Fluid and Nutrient Replenisher
PRESCRIBING INFORMATION Dextrose Injection USP (Concentrated Dextrose for Intravenous Administration) 50% (500 mg/ml) Fluid and Nutrient Replenisher Pfizer Canada Inc. 17300 Trans-Canada Highway Kirkland,
More informationCOMPANY CORE PACKAGE INSERT CCPI (PI/CORE/ENGLISH)
COMPANY CORE PACKAGE INSERT CCPI (PI/CORE/ENGLISH) HUMAN ALBUMIN 20 % BEHRING Rev.: 05-MAR-2008 / PEI approval 26.02.08 Supersedes previous versions Rev.: 28-NOV-2007 / Adaptation to Core SPC Rev.: 02-JAN-2007
More information(angiotensin II) injection for intravenous infusion
ADMINISTERING GIAPREZA TM (angiotensin II) injection for intravenous infusion Visit www.giapreza.com INITIATE Recommended starting dose of GIAPREZA is 20 ng/kg/min, which is equivalent to 0.02 mcg/kg/min
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Albuman 40 g/l is a solution containing 40 g/l (4%) of total protein of which at least 95% is human albumin.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Albuman 40 g/l solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Albuman 40 g/l is a solution containing 40 g/l (4%)
More informationNormosol -R and 5% Dextrose Injection MULTIPLE ELECTROLYTES AND 5% DEXTROSE INJECTION TYPE 1, USP For Replacing Acute Losses of Extracellular Fluid
Normosol -R and 5% Dextrose Injection MULTIPLE ELECTROLYTES AND 5% DEXTROSE INJECTION TYPE 1, USP For Replacing Acute Losses of Extracellular Fluid R x only Flexible Plastic Container DESCRIPTION Normosol-R
More informationIV Fluids. I.V. Fluid Osmolarity Composition 0.9% NaCL (Normal Saline Solution, NSS) Uses/Clinical Considerations
IV Fluids When administering IV fluids, the type and amount of fluid may influence patient outcomes. Make sure to understand the differences between fluid products and their effects. Crystalloids Crystalloid
More informationSodium Chloride Injection, USP in VIAFLEX Plastic Container
Sodium Chloride Injection, USP in VIAFLEX Plastic Container DESCRIPTION Sodium Chloride Injection, USP is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment in single dose containers
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Aqupharm 1 (9 mg/ml) solution for injection/infusion (UK/IE) Natriumklorid Animalcare 9 mg/ml solution for injection/infusion
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Synthamin 14, 8.5% Amino Acid Intravenous Infusion
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Synthamin 14, 8.5% Amino Acid Intravenous Infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION L-Leucine Ph. Eur 0.620% w/v L-Isoleucine
More informationHuman Albumin 200 g/l Baxter is a solution containing 200 g/l of total protein of which at least 95% is human albumin.
1. NAME OF THE MEDICINAL PRODUCT Human Albumin 200 g/l Baxter Solution for Infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Human Albumin 200 g/l Baxter is a solution containing 200 g/l of total protein
More information1 INDICATIONS AND USAGE. 1.1 Limitation of Use FULL PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TRIFERIC safely and effectively. See full prescribing information for TRIFERIC. TRIFERIC (ferric
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Albunorm 20%, 200 g/l, solution for infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Albunorm 20% is a solution containing 200 g/l
More informationCSL Behring LLC Albuminar -25 US Package Insert Albumin (Human) USP, 25% Revised: 01/2008 Page 1
Page 1 CSL Behring Albuminar -25 Albumin (Human) USP, 25% R x only DESCRIPTION Albuminar -25, Albumin (Human) 25%, is a sterile aqueous solution of albumin obtained from large pools of adult human venous
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Sodium Chloride Infusion BP 0.9%, as Steriflex No. 1 or freeflex 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Steriflex No. 1 has the
More informationVoluven 10 % solution for infusion Hydroxyethyl starch (HES 130/0.4) in isotonic sodium chloride solution
0xxxxx1_00_UK_Voluven_10%_V003:0xxxxx1_00_UK_Voluven_10%_V003 10.02.2016 10:36 Uhr Seite 1 5 6 1 Electrolytes: Na + 154 mmol/l Cl 154 mmol/l Theoretical osmolarity: 308 mosm/l Titrable acidity: 1.0 mmol
More informationPRODUCT INFORMATION. NAME OF THE MEDICINE Compound Sodium Lactate (Hartmann's) Solution for Injection
PRODUCT INFORMATION NAME OF THE MEDICINE Compound Sodium Lactate (Hartmann's) Solution for Injection DESCRIPTION Molecular formulae. Potassium chloride: KCl; sodium chloride: NaCl; calcium chloride dihydrate:
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION CONTRAINDICATIONS
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use DEXTROSE INJECTION 20%, 30%, 40%, 50% and 70% safely and effectively. See full prescribing information
More information(human albumin solution) POM SUMMARY OF PRODUCT CHARACTERISTICS
albunorm TM 20% (human albumin solution) POM SUMMARY OF PRODUCT CHARACTERISTICS UK IRELAND and Ireland Octapharma Limited The Zenith Building, 26 Spring Gardens Manchester M2 1AB United Kingdom 1. Name
More information3 DOSAGE FORMS AND STRENGTHS
PATADAY- olopatadine hydrochloride solution/ drops Alcon Laboratories, Inc. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PATADAY safely
More informationReference ID:
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TRIFERIC safely and effectively. See full prescribing information for TRIFERIC. TRIFERIC (ferric
More informationProceeding of the LAVECCS
Close this window to return to IVIS Proceeding of the LAVECCS Congreso Latinoamericano de Emergencia y Cuidados Intensivos Ju1. 28-30, 2011 Santiago de Chile, Chile www.laveccs.org Reprinted in IVIS with
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Alburex 5, 50 g/l, solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Alburex 5 is a solution containing 50 g/l of total
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Albunorm 5%, 50 g/l, solution for infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Albunorm 5% is a solution containing 50 g/l of total
More informationAPPENDIX 1 SUMMARY OF PRODUCT CHARACTERISTICS
SmPC Country: Lebanon Date of approval : 17/08/2011 Procedure : National APPENDIX 1 SUMMARY OF PRODUCT CHARACTERISTICS 1- NAME OF THE MEDICINAL PRODUCT DECAN, concentrate for solution for infusion 2- QUALITATIVE
More informationGALLIUM CITRATE Ga 67 INJECTION
511945-0903 September 2003 USA Bristol-Myers Squibb Medical Imaging 331 Treble Cove Road N. Billerica, MA 01862 USA GALLIUM CITRATE Ga 67 INJECTION FOR DIAGNOSTIC USE DESCRIPTION: Gallium Citrate Ga 67
More information0.45% Sodium Chloride Injection, USP
PRESCRIBING INFORMATION 0.45% Sodium Chloride Injection, USP IV Fluid and Electrolyte Replenisher Baxter Corporation Mississauga, Ontario L5N 0C2 Canada Date of Revision: November 22, 2013 Submission Control
More informationReference ID:
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and
More informationPotassium Chloride in 0.9% Sodium Chloride Injection, USP in Plastic Container
PRESCRIBING INFORMATION Potassium Chloride in 0.9% Sodium Chloride Injection, USP in Plastic Container VIAFLEX Container 20mmol/L Potassium Chloride in Sodium in 0.9% Chloride Injection 40mmol/L Potassium
More informationINTRAVENOUS SOLUTIONS WITH POTASSIUM CHLORIDE POTASSIUM CHLORIDE IN LACTATED RINGER S AND 5% DEXTROSE INJECTION, USP Flexible Plastic Container
INTRAVENOUS SOLUTIONS WITH POTASSIUM CHLORIDE POTASSIUM CHLORIDE IN LACTATED RINGER S AND 5% DEXTROSE INJECTION, USP Flexible Plastic Container R x only DESCRIPTION Intravenous solutions with potassium
More informationSodium Bicarbonate Injection, USP
Sodium Bicarbonate Injection, USP FOR THE CORRECTION OF METABOLIC ACIDOSIS AND OTHER CONDITIONS REQUIRING SYSTEMIC ALKALINIZATION. Plastic Ansyr II Syringe R x only DESCRIPTION Sodium Bicarbonate Injection,
More informationmultibic potassium-free multibic 2 mmol/l potassium multibic 3 mmol/l potassium multibic 4 mmol/l potassium
FRESENIUS MEDICAL CARE Deutschland GmbH Name(s) of the medicinal product(s): -free 2 mmol/l 3 mmol/l 4 mmol/l Pharmaceutical form: Solution for haemodialysis/haemofiltration Procedure number(s): DE/H/0388/001-004/II/030/G
More informationFLUID THERAPY: IT S MORE THAN JUST LACTATED RINGERS
FLUID THERAPY: IT S MORE THAN JUST LACTATED RINGERS Elisa M. Mazzaferro, MS, DVM, PhD, DACVECC Cornell University Veterinary Specialists, Stamford, CT, USA Total body water constitutes approximately 60%
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Albunorm 20%, 200g/l, solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Albunorm 20% is a solution containing 200 g/l
More informationAquaMEPHYTON (PHYTONADIONE) Aqueous Colloidal Solution of Vitamin K 1
9073025 INJECTION AquaMEPHYTON (PHYTONADIONE) Aqueous Colloidal Solution of Vitamin K 1 WARNING - INTRAVENOUS AND INTRAMUSCULAR USE Severe reactions, including fatalities, have occurred during and immediately
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use epinastine hydrochloride ophthalmic solution safely and effectively. See full prescribing information
More informationCLINICAL PHARMACOLOGY
SODIUM CHLORIDE- sodium chloride injection, solution ---------- Sodium Chloride Injections USP DESCRIPTION Each 100 ml of 0.9% Sodium Chloride Injection USP contains: Sodium Chloride USP 0.9 g; Water for
More informationDBL NALOXONE HYDROCHLORIDE INJECTION USP
Name of medicine Naloxone hydrochloride Data Sheet New Zealand DBL NALXNE HYDRCHLRIDE INJECTIN USP Presentation DBL Naloxone Hydrochloride Injection USP is a sterile, clear, colourless solution, free from
More information(human albumin solution) POM SUMMARY OF PRODUCT CHARACTERISTICS
albunorm TM 5% (human albumin solution) POM SUMMARY OF PRODUCT CHARACTERISTICS UK IRELAND and Ireland Octapharma Limited The Zenith Building, 26 Spring Gardens Manchester M2 1AB United Kingdom 1. Name
More informationELSPAR (asparaginase) For injection, intravenous or intramuscular Initial U.S. Approval: 1978
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Elspar safely and effectively. See full prescribing information for Elspar. ELSPAR (asparaginase)
More informationVI.2 ELEMENTS FOR A PUBLIC SUMMARY (VOLUVEN 10%)
VI.2 ELEMENTS FOR A PUBLIC SUMMARY (VOLUVEN 10%) VI.2.1 OVERVIEW OF DISEASE EPIDEMIOLOGY Hypovolaemia is a state of decreased or reduced circulating blood volume which can be caused by a number of medical
More informationAdminister as an intravenous infusion over 35 to 60 minutes (2.1, 2.3) Dilution required prior to administration (2.2)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use EXONDYS 51 safely and effectively. See full prescribing information for EXONDYS 51. EXONDYS 51 (eteplirsen)
More informationImportant Safety Information for Feraheme (ferumoxytol) Injection
Dear Radiologist: (ferumoxytol) Injection for intravenous (IV) use is an IV iron replacement product indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease
More informationGuideline on core SmPC for human albumin solution (EMA/CHMP/BPWP/494462/2011/Rev.3)
26 July 2018 EMA/CHMP/BPWP/494462/2011 rev.3 Committee for Medicinal Products for Human Use (CHMP) (EMA/CHMP/BPWP/494462/2011/Rev.3) Adopted by CHMP for release for consultation 21 June 2012 Start of public
More informationPage 1 of CONTRAINDICATIONS None (4)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AXUMIN safely and effectively. See full prescribing information for AXUMIN. AXUMIN (fluciclovine
More information0.45% Sodium Chloride Injection, USP
PRESCRIBING INFORMATION 0.45% Sodium Chloride Injection, USP Solution for Infusion Intravenous Fluid and Electrolyte Replenisher Baxter Corporation Mississauga, Ontario L5N 0C2 Canada Date of Revision:
More informationPackage leaflet: information for the user. Prismasol 2 mmol/l Potassium Solution for haemodialysis/haemofiltration
Package leaflet: information for the user Prismasol 2 mmol/l Potassium Solution for haemodialysis/haemofiltration Calcium chloride dihydrate/ magnesium chloride hexahydrate/ glucose monohydrate/ lactic
More informationPHARMACY DOSING AND ORDERING GUIDE
PHARMACY DOSING AND ORDERING GUIDE FIRST AND ONLY APPROVED TREATMENT FOR PATIENTS WITH VOD WITH RENAL OR PULMONARY DYSFUNCTION POST HSCT VOD=veno-occlusive disease Indication Defitelio (defibrotide sodium)
More informationSUMMARY OF PRODUCT CHARACTERISTICS 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS PRODUCT SUMMARY 1. NAME OF THE MEDICINAL PRODUCT Sterile Potassium Chloride Concentrate 15%. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 15% of Potassium Chloride in
More informationGUIDELINES FOR WEIGHT-BASED DOSING AND INFUSION
GUIDELINES FOR WEIGHT-BASED DOSING AND INFUSION Includes Example dose calculation wheel Preparation and administration information for healthcare professionals Please see enclosed full Prescribing Information,
More informationVITAMIN K 1 INJECTION Phytonadione Injectable Emulsion, USP Aqueous Dispersion of Vitamin K 1
VITAMIN K 1 INJECTION Phytonadione Injectable Emulsion, USP Aqueous Dispersion of Vitamin K 1 Ampul Rx only Protect from light. Keep ampuls in tray until time of use. WARNING INTRAVENOUS AND INTRAMUSCULAR
More informationAminosteril N-Hepa 8%, solution for infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Title Page Information Aminosteril N-Hepa 8% November 2001 1 (7) 1. NAME OF THE MEDICINAL PRODUCT Aminosteril N-Hepa 8%, solution for infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1000 ml solution
More informationADMINISTRATION GUIDE
DOSING AND ADMINISTRATION GUIDE INDICATION LARTRUVO is indicated, in combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which
More informationSee 17 for PATIENT COUNSELING INFORMATION.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PRAXBIND safely and effectively. See full prescribing information for PRAXBIND. PRAXBIND (idarucizumab)
More informationKHAPZORY (levoleucovorin) for injection, for intravenous use Initial U.S. Approval: 1952 (d,l-leucovorin)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KHAPZORY safely and effectively. See full prescribing information for KHAPZORY. KHAPZORY (levoleucovorin)
More informationADVERSE REACTIONS Most common adverse reactions during treatment: nausea, vomiting, and tachycardia. (6)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AKOVAZ safely and effectively. See full prescribing information for AKOVAZ. AKOVAZ (ephedrine sulfate
More information*Sections or subsections omitted from the full prescribing information are not 6 ADVERSE REACTIONS
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and
More informationImportant Prescribing Information
Important Prescribing Information Subject: Temporary importation of Potassium Chloride (KCl) Injection, Concentrate, 2 meq/ml to address drug shortage issues July 11, 2018 Dear Healthcare Professional,
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Potassium Chloride 0.15% w/v & Sodium Chloride 0.9% w/v Solution for Infusion
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Potassium Chloride 0.15% w/v & Sodium Chloride 0.9% w/v Solution for Infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Potassium Chloride
More informationKASHVET VETERINARIAN RESOURCES FLUID THERAPY AND SELECTION OF FLUIDS
KASHVET VETERINARIAN RESOURCES FLUID THERAPY AND SELECTION OF FLUIDS INTRODUCTION Formulating a fluid therapy plan for the critical small animal patient requires careful determination of the current volume
More informationBlood products and plasma substitutes
Blood products and plasma substitutes Plasma substitutes Dextran 70 and polygeline are macromolecular substances which are metabolized slowly; they may be used to expand and maintain blood volume in shock
More informationNEW ZEALAND DATA SHEET
1. PRODUCT NAME ADDAVEN (infusion, solution concentrate) NEW ZEALAND DATA SHEET 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 10 ml ampoule of Addaven contains: Chromic chloride hexahydrate 53.33 µg
More informationDosing and Administration Guide for ARZERRA
Dosing and Administration Guide for ARZERRA Indications ARZERRA (ofatumumab) is indicated: In combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic
More informationFLEXBUMIN 5% Albumin (Human), USP, 5% Solution For intravenous use Initial U.S. Approval: 2005
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FLEXBUMIN 5% safely and effectively. See full prescribing information for FLEXBUMIN 5%. FLEXBUMIN
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Human Albumin Biotest 20%, solution for infusion Human albumin
PACKAGE LEAFLET: INFORMATION FOR THE USER Human Albumin Biotest 20%, solution for infusion Human albumin Read this entire leaflet carefully before you start using this medicine, because it contains important
More informationOSMITROL INJECTION Mannitol Injection
Page 1 of 9 PRESCRIBING INFORMATION OSMITROL INJECTION Mannitol Injection 10% OSMITROL INJECTION 20% OSMITROL INJECTION USP Solution for Infusion Osmotic Diuretics Baxter Corporation Mississauga, Ontario
More information2. PRESCRIPTION STATUS/RESTRICTION OF SALES TO PHARMACIES ONLY 3. COMPOSITION OF THE MEDICINAL PRODUCT
Title Page Product Information May 2000 1 (6) Product Nephrotect 1. NAME OF THE MEDICINAL PRODUCT Nephrotect 2. PRESCRIPTION STATUS/RESTRICTION OF SALES TO PHARMACIES ONLY For sale in pharmacies only 3.
More informationFor the use of a registered medical practitioner or a Hospital or a Laboratory only
For the use of a registered medical practitioner or a Hospital or a Laboratory only Intravenous Fat Emulsion NIRPID * Intravenous fat Emulsion DESCRIPTION: NIRPID * is a stable fat emulsion prepared from
More informationGLUCEPTATE. Technetium Tc 99m Gluceptate Kit DIAGNOSTIC DESCRIPTION
27194 0001E m TM GLUCEPTATE Technetium Tc 99m Gluceptate Kit DIAGNOSTIC DESCRIPTION The kit consists of reaction vials which contain the sterile, non-pyrogenic, nonradioactive ingredients necessary to
More informationPRESCRIBING INFORMATION. Sodium Bicarbonate Injection USP 42mg/ml (4.2%), 75mg/ml (7.5%), 84mg/ml (8.4%) Sterile solution ALKALIZER
PRESCRIBING INFORMATION Sodium Bicarbonate Injection USP 42mg/ml (4.2%), 75mg/ml (7.5%), 84mg/ml (8.4%) Sterile solution Lifeshield ABBOJECT Single-dose Syringes and Flipp Vial ALKALIZER FOR CORRECTION
More informationTrifluridine Ophthalmic Solution, 1% Sterile
Trifluridine Ophthalmic Solution, 1% Sterile DESCRIPTION Trifluridine (also known as trifluorothymidine, F 3 TdR,F 3 T), is an antiviral drug for topical treatment of epithelial keratitis caused by herpes
More information* Sections or subsections omitted from the Full Prescribing Information are not listed.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ANDEXXA safely and effectively. See Full Prescribing Information for ANDEXXA. ANDEXXA (coagulation
More informationVersion: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING Product Identifier Material Name: VETSTARCH
Page 1 of 7 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING Product Identifier Trade Name: Synonyms: Chemical Family: VETSTARCH 6% hydroxyethyl starch 130/0.4 in 0.9% Sodium Chloride
More informationReferral Form. Referring physician s phone: Referring physician s fax:
(ferumoxytol) Injection for intravenous (IV) use Referral Form Referring gphysician s name: Referring physician s phone: Referring physician s fax: Dear Dr or Infusion Center : I am referring my patient
More informationPACKAGE INSERT CALCIUM GLUCONATE INJECTION, USP 10% Electrolyte Replenisher mosmol/ml 680 mosmol/l Ca meq/ml ph
CALCIUM GLUCONATE INJECTION, USP 10% Electrolyte Replenisher 0.68 mosmol/ml 680 mosmol/l Ca ++ 0.465 meq/ml ph 6.0 8.2 DESCRIPTION Calcium Gluconate Injection, USP is a sterile, nonpyrogenic supersaturated
More informationDosing and Administration Guide for ARZERRA
Dosing and Administration Guide for ARZERRA INDICATIONS for ARZERRA (ofatumumab) In combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL)
More informationVIROPTIC Ophthalmic Solution, 1% Sterile (trifluridine ophthalmic solution)
VIROPTIC Ophthalmic Solution, 1% Sterile (trifluridine ophthalmic solution) PRODUCT OVERVIEW: VIROPTIC SOLUTION DESCRIPTION VIROPTIC is the brand name for trifluridine (also known as trifluorothymidine,
More informationPRODUCT INFORMATION. DESCRIPTION Addaven is a concentrated trace element solution for infusion which is clear and colourless to slightly yellow.
PRODUCT INFORMATION Addaven NAME OF MEDICINE Addaven is a concentrated trace element solution containing the following simple salts: chromic chloride hexahydrate (CAS No.:10060-12-5), cupric chloride dihydrate
More informationACETYLCYSTEINE INJECTION
ACETYLCYSTEINE INJECTION 1. Name of the medicinal product Acetylcysteine 200 mg/ml Injection 2. Qualitative and quantitative composition Acetylcysteine 200mg per ml (as N-acetylcysteine) Each 10ml ampoule
More informationReference ID:
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ENDARI TM safely and effectively. See full prescribing information for ENDARI. ENDARI (L-glutamine
More information